All times listed are Eastern Standard Time.

Program is subject to change

Saturday, February 3, 2024

Start 7:50 am
Welcome and Overview 
Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini

Session I: OCTomics

• New Imaging Findings from High-Res OCT
• Trizonal Distribution of Drusen and SDD with En Face OCT Maps to Photoreceptor Density
• Multimodal Assessment of OCT Biomarkers of GA and its Precursors
• Precursor Lesions for Development of Atrophy in AMD
• A Comparison Between the Grading of iRORA and cRORA on OCT B-Scans with the Grading of Persistent Hype transmission Defects on En Face OCT images
• Algorithms to Detect and Quantify Drusen, Choroidal Hypertransmission Defects, and Hyperpigmentation Applicable to Both SD-OCTA and SS-OCTA Scans
• SS-OCTA Imaging of High-Risk OCT Biomarkers that Predict Disease Progression in Intermediate AMD
• Automated Segmentation and Quantification of Calcifying Drusen Applicable to Both SD-OCT and SS-OCT Scans
• Automated Detection of Choroidal Hypertransmission Defects with Both SD-OCTA and SS-OCTA Scans
• Automated Measurement of Outer Retinal Thickness as a Biomarker for Assessing AMD Progression
• SS-OCT Angiography for Mapping Retinal Capillary Structure and Assessing Flow
• Leakage Detection Through OCT-Angiography Using Artificial Intelligence-Inferred Fluorescein Angiography

Session II: Non-Exudative AMD

• Moderators: Jaclyn L. Kovach, Zohar Yehoshua, and Philip J. Rosenfeld
• Early Onset AMD: Lessons to Learn
• Zonal Resolution of Widespread Drusen
• Lysolipids are Prominent in Subretinal Drusenoid Deposits
• The Importance of Basal Laminar Deposits in AMD
• Classification and Regression Tree (CART) Analyses for Intermediate Age-Related Macular Degeneration---AREDS/AREDS2
• Impact of Risk Factors on Progression and Vision Impairment of Geographic Atrophy in a Korean Patient Cohort
• Predictors of GA Development in Type 3 MNV Treated with Anti-VEGF Therapy
• Foundation Models and AMD

Session III: Emerging Therapies for Non-Exudative AMD
Moderators: Ninel Z. Gregori, Philip J. Rosenfeld, and Raquel Goldhardt

• Balloon Angioplasty for AMD: An Update
• Optogenetics for Restoring Vision in Geographic Atrophy Secondary to Advanced AMD
• AVD-104 for Geographic Atrophy: Glyco-Immunologic Modulation of Macrophage Activity
• Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy
• Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy: Results of the ARCHER Study
• Elamipretide Update - Entering Phase 3
• LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration

Session IV: Visual FunctionTesting and Complement Inhibition for the Treatment of GA

• Comparability of Functional Retinal Testing Across Devices in AMD Patients and Normal Controls
• Functional Endpoints in Geographic Atrophy: An Analysis from the Chroma and Spectri Clinical Trials
• The Use of High Density Focal Photopic Microperimetry to Follow Response to Anti-Complement Therapy in Patients with Geographic Atrophy
• AI in GA: How to Screen, Identify and Monitor Patients in the Real-World
• 2-year Expanded Efficacy Data from the GATHER 2 Trial
• Safety Findings from the GATHER Program Including 2-year Results from the GATHER2 Trial
• Functional Consequences of Avacincaptad Treatment in the GATHER Trials
• Hypertransmission Defects and Ellipsoid Zone Integrity Dynamics in the GATHER Clinical Trials
• Does Initial GA Growth Rate Predict GA Lesion Growth Rate and Response to Therapy at 2 years: 2-year Follow-up Data from GATHER 2
• Update on Pegcetacoplan for the Treatment of Geographic Atrophy
• Functional Benefits with Pegcetacoplan
• An Anchored-Matching Adjusted Indirect Comparison of the Phase 3 Trials for GA: Pegcatacoplan vs. Avacincaptad Pegol

Session V: Real World Experience with Complement Inhibition for GA

Moderators: Thomas A. Albini, Philip J. Rosenfeld, and Janet L. Davis

• Management of Geographic Atrophy with Pegcetacoplan in Clinical Practice: First Time Data Presentation from a Large Multi-Center Study
• Defining Occlusive Retinal Vasculitis
• Retinal Vasculitis Following Intravitreal Pegcetacoplan: An Update from the ASRS ReST Committee
• Panel Discussion: Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD

 Session VI: Emerging Therapies for Exudative AMD

Moderators: Luis J. Haddock, Stephen G. Schwartz, and Nicolas A. Yannuzzi

• KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study
• Clinical Trails Evaluating LX102 Anti-VEGF Gene Therapy in Patients with Wet AMD
• Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase 2 Pharmacodynamic Study
• First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD
• THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration
• THE DAVIO 2 TRIAL: Subgroup Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration
• Home OCT Guided Management of Patients with nAMD
• Longitudinal AI-based Fluid Quantification and its Implication for Remote Patient Monitoring
• Is 12 Weeks the New Norm? What Determines Why Some Patients Need More Frequent Intravitreal Dosing?

Session VII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: High-Dose Aflibercept

Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld

96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study

• Aflibercept 8mg for PCV Subgroup in the PULSAR Study
• Aflibercept 8mg for Diabetic Macular Edema: Update on the 96-Week Results of the PHOTON Study
• Aflibercept 8 mg: Safety Outcomes from the CANDELA, PULSAR, and PHOTON Studies
• Discussion

Sunday, February 4, 2024

Start 8:00 am

Session VIII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: Faricimab

Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld

• Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME
• Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME
• Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies
• Voyager Study- Update on Faricimab in the Real World
• Insights from Clinical Practice - Review of First Year Experience with Faricimab in the Real World
• Discussion

Session IX: Diabetic Retinopathy and Retinal Vascular Diseases

Moderators: Harry W. Flynn, Jr., Justin H. Townsend, and Basil Williams

• OCT Angiography in Diabetic Retinopathy
• Predictors of Diabetic Retinopathy Worsening on Ultrawide Field Imaging
• OCS-01 for Diabetic Macular Edema: A New Perspective on Dexamethasone
• Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: Interim Results from the First In-Human Phase 2 RIPPLE-1 Trial
• Subgroup analysis and effect of disease severity in the BEHOLD phase 2 study of UBX1325 in DM
• RZ402: A Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema
• Oral 3TC for Center-Involved Diabetic Macular Edema: A Randomized Clinical Trial
• APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as the Endpoint
• The Path Forward for PDS: Technical Data Supporting Device Improvements and Septum Dislodgement Mitigation
• The impact of Continuous Delivery of Ranibizumab with PDS on Retinal Nonperfusion in Diabetic Retinal Disease
• Combined Analysis of BUTTERFLEYE/FIREFLEYE NEXT Aflibercept for ROP Treatment Trials and the Emerging ROP Prevention Trials
• What’s New with MacTel2?
• Post-Program Test and Closing Remarks
• Meeting Adjourns